Literature DB >> 29794206

Aerosol Delivery Devices for Obstructive Lung Diseases.

Roy A Pleasants1, Dean R Hess2.   

Abstract

Drug delivery by inhalation is the principal strategy to treat obstructive lung diseases, which affect about 15% of the population in the United States. Aerosol delivery devices have evolved over more than 60 years from the basic pressurized metered-dose inhaler and nebulizer to numerous types of inhalers and devices, including valved holder chambers, dry powder inhalers, soft mist inhalers, as well as smart inhalers and nebulizers. Although these devices improve a patient's ability to self-administer medication, many problems with optimal delivery still exist. Appropriate selection and repeated patient education can help lessen the problems with these devices. Aerosol science is evolving, with methods of measurement that include radio-scintigraphy and magnetic resonance imaging, to provide a better understanding of aerosol delivery and effects. Understanding the science and clinical application of aerosol drug delivery can substantially aid clinicians in optimizing these therapies for their patients.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  COPD; asthma; dry powder inhalers; inhalational therapies; lung deposition; metered-dose inhalers; nebulization; patient education; smart inhalers

Mesh:

Substances:

Year:  2018        PMID: 29794206     DOI: 10.4187/respcare.06290

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  13 in total

Review 1.  Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.

Authors:  Roy A Pleasants; Peter A Radlowski; H Edward Davidson
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

Review 2.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

3.  Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs.

Authors:  Snehal K Shukla; Apoorva Sarode; Dipti D Kanabar; Aaron Muth; Nitesh K Kunda; Samir Mitragotri; Vivek Gupta
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2021-07-15

4.  Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD.

Authors:  Alexander G Duarte; Leon Tung; Wei Zhang; En Shuo Hsu; Yong-Fang Kuo; Gulshan Sharma
Journal:  Chronic Obstr Pulm Dis       Date:  2019-07-24

5.  Aerosolization of COVID-19 and Contamination Risks During Respiratory Treatments.

Authors:  Cassandra D Benge; John Alan Barwise
Journal:  Fed Pract       Date:  2020-04

6.  What makes flunisolide different among inhaled corticosteroids used for nebulization: a close look at the role of aqueous solubility.

Authors:  Ahmad Kantar
Journal:  Multidiscip Respir Med       Date:  2021-01-15

7.  The Clinical Practice and Best Aerosol Delivery Location in Intubated and Mechanically Ventilated Patients: A Randomized Clinical Trial.

Authors:  Chuanlin Zhang; Jie Mi; Zeju Zhang; Xueqin Wang; Yunxiao Zhu; Xinyi Luo; Ruiying Gan; Xiaoya Chen; Yujun Zou
Journal:  Biomed Res Int       Date:  2021-04-03       Impact factor: 3.411

8.  Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.

Authors:  Martin Anderson; Kathryn Collison; M Bradley Drummond; Melanie Hamilton; Renu Jain; Neil Martin; Richard A Mularski; Mike Thomas; Chang-Qing Zhu; Gary T Ferguson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-12

Review 9.  Inhalation delivery technology for genome-editing of respiratory diseases.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-05       Impact factor: 15.470

Review 10.  Nebulized Therapies in COPD: Past, Present, and the Future.

Authors:  Igor Z Barjaktarevic; Aaron P Milstone
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.